Answered all questions I had
At 40 mg/mL , 60 units equals 24 mg
Stomach acid-resistant capsules (DRcaps) further protect stability in these S-acetyl glutathione pills
[101] Clinical trials with Sotagliflozin show promising results that suggest interplay from both SGLT1 and SGLT2 inhibition
The influence of diabetes medications on meal test results, especially in cohort 2, should also be considered
Frequencies reflect SmPC classifications: Very common (more than 1 in 10 people): nausea, vomiting, diarrhoea, decreased appetite, particularly during dose escalation Common (up to 1 in 10 people): increased heart rate, injection-site reactions, fatigue, constipation, dyspepsia, abdominal discomfort Uncommon to rare but clinically important: acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis) Additional safety considerations per the UK SmPC include: Hypoglycaemia : the risk rises when tirzepatide is used with insulin or a sulfonylurea
